Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors
Status:
Completed
Trial end date:
2019-02-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the effect of a single dose of 40 mg
sapanisertib (MLN0128) on the electrocardiographic QT/QTc interval in participants with
advanced solid tumors.